To improve patient selection for breast brachytherapy, "suitability" criteria are proposed but still require empiric validation. In this cohort of older breast cancer patients, there was an increased risk of subsequent mastectomy after breast brachytherapy compared with external beam radiation therapy. Suitability criteria identified patients with the lowest absolute, but not relative, risk of mastectomy.
Summary
To improve patient selection for breast brachytherapy, "suitability" criteria are proposed but still require empiric validation. In this cohort of older breast cancer patients, there was an increased risk of subsequent mastectomy after breast brachytherapy compared with external beam radiation therapy. Suitability criteria identified patients with the lowest absolute, but not relative, risk of mastectomy.
Purpose: Brachytherapy after lumpectomy is an increasingly popular breast cancer treatment, but data concerning its effectiveness are conflicting. Recently proposed "suitability" criteria guiding patient selection for brachytherapy have never been empirically validated. Methods: Using the Surveillance, Epidemiology, and End ResultseMedicare linked database, we compared women aged 66 years or older with invasive breast cancer (nZ28,718) or ductal carcinoma in situ (nZ7229) diagnosed from 2002 to 2007, treated with lumpectomy alone, brachytherapy, or external beam radiation therapy (EBRT). The likelihood of breast preservation, measured by subsequent mastectomy risk, was compared by use of multivariate proportional hazards, further stratified by American Society for Radiation Oncology (ASTRO) brachytherapy suitability groups. We compared 1-year postoperative complications using the c 2 test and 5-year local toxicities using the log-rank test. Results: For patients with invasive cancer, the 5-year subsequent mastectomy risk was 4.7% after lumpectomy alone (95% confidence interval [CI], 4.1%-5.4%), 2.8% after brachytherapy (95% CI, 1.8%-4.3%), and 1.3% after EBRT (95% CI, 1.1%-1.5%) (P<.001). Compared with lumpectomy alone, brachytherapy achieved a more modest reduction in adjusted risk (hazard ratio [HR] , 0.61; 95% CI, 0.40-0.94) than achieved with EBRT (HR, 0.22; 95% CI, 0.18-0.28). Relative risks did not differ when stratified by ASTRO suitability group (PZ.84 for interaction), although ASTRO "suitable" patients did show a low absolute subsequent mastectomy risk, with a minimal absolute difference in risk after brachytherapy (1.6%; 95% CI, 0.7%-
Introduction
Breast brachytherapy after lumpectomy for early breast cancer is an increasingly popular radiation treatment approach, increasingly used in lieu of standard whole-breast irradiation (1, 2) . Brachytherapy limits radiation treatment to the tissue surrounding the lumpectomy cavity and conveniently accelerates treatment completion within 1 to 2 weeks (3). Yet controversy persists over whether this technique should be considered a standard of care, given the lack of clarity regarding which patient subgroups may derive the greatest benefit and which subgroups may incur potential harm from this treatment. One recent study found that older women with invasive breast cancer had decreased breast-preservation and higher complication rates after brachytherapy compared with standard radiation, but that analysis did not stratify by pathologic factors (1) .
To guide clinicians, the American Society for Radiation Oncology (ASTRO) proposed "suitability" criteria to guide brachytherapy use in everyday practice, stratifying patients as "suitable," "cautionary," and "unsuitable" (3) . The suitable group identifies low-risk patients with favorable local control outcomes (4, 5) , although National Comprehensive Cancer Network guidelines suggest that adjuvant radiation could be forgone in many such suitable patients (3) (4) (5) . Importantly, ASTRO categories have not been empirically validated for the ability to distinguish who might benefit from brachytherapy, particularly in comparison with the alternatives of lumpectomy alone (4) or whole-breast irradiation.
Given the existing heterogeneousdand sometimes conflictingdrecommendations, a direct comparison is warranted of outcomes after lumpectomy alone versus adjuvant brachytherapy versus adjuvant external beam radiation therapy (EBRT). Comparing risk-benefit profiles for these treatments is essential for prospectively stratifying patients' risk and guiding treatment decisions. Accordingly, in a cohort of Medicare patients diagnosed with early invasive breast cancer or ductal carcinoma in situ (DCIS), we sought to compare the following among treatment groups: (1) the likelihood of breast preservation after treatment, (2) the validity of suitability categories for modifying the likelihood of breast preservation, and (3) the risks of postoperative complications and local toxicities. 
Methods

Outcomes
Subsequent mastectomy was defined as a claim for mastectomy identified from 1 year after diagnosis to December 31, 2009 (last date of follow-up). Postoperative complications (infectious and noninfectious) were determined by claims reported within 1 year of diagnosis. Local toxicities (breast pain, rib fracture, fat necrosis, and radiation pneumonitis) were determined by claims reported between the diagnosis date and date of last follow-up.
ASTRO suitability groupings
Patients with invasive cancer were classified as suitable, cautionary, or unsuitable for brachytherapy, according to groupings adapted from ASTRO consensus criteria (3) and recently published methods (2) . Suitable patients had estrogen receptor (ER)epositive tumors, 2 cm or less in size, with invasive ductal, mucinous, or tubular histology; no extensive intraductal component; and clinically and pathologically node-negative disease with documentation of surgical and/or pathologic assessment of axillary lymph nodes. On the basis of the study inclusion criterion of age 66 years or older, all patients in this sample met the ASTRO age criterion. In our sample the subset of patients aged 70 years or older was classified as "older suitable."
Unsuitable patients included those with T3/T4 disease, tumor size greater than 3 cm, documented nodal involvement, or no nodal sampling for those with invasive disease. Cautionary patients included those without unsuitable features but who had invasive cancer with tumor size between 2.1 and 3.0 cm or any of the following features with total tumor size of 3.0 cm or less: extensive intraductal component, invasive lobular histology, or ER-negative disease. Candidate patients with DCIS are typically considered ASTRO cautionary. The DCIS subset of cautionary patients were analyzed separately, as explained below in the statistical analysis section. Patients not meeting any of these criteria were considered "unclassified." Surgical margin status, lymphovascular space invasion, and multicentricity are unavailable in the SEER-Medicare dataset (2) .
were determined by use of the Pearson c 2 test. The CochranArmitage test for trend was used to test for temporal changes in treatment.
Subsequent mastectomy risk
To address the first objective, the cumulative incidence of subsequent mastectomy for each radiation treatment type was calculated with the Kaplan-Meier method for the overall cohort and separately for patients with invasive cancer and DCIS. The logrank test compared all paired comparisons.
We used multivariate proportional hazards regression to test whether radiation treatment type was associated with subsequent mastectomy risk after adjusting for patient, tumor, and sociodemographic covariates. Interactions were tested with the likelihood ratio test. Because the interaction term between treatment group and tumor behavior (invasive vs DCIS) was statistically significant (PZ.01 for interaction), analyses for invasive cancer versus DCIS were conducted separately.
A secondary validation model (for invasive cancer) used propensity score analysis with 1:1 matched cohorts: lumpectomy alone matched to EBRT, lumpectomy alone matched to brachytherapy, and EBRT matched to brachytherapy. We determined propensity scores using logistic modeling adjusting for baseline covariates (6) . Proportional hazards regression stratified by matched pair was used to determine associations between radiation treatment type and subsequent mastectomy risk.
ASTRO-stratified analysis
To address the second objective, we tested associations between radiation type and subsequent mastectomy risk within each ASTRO risk group (suitable, cautionary, unsuitable, and unclassified) using the Kaplan-Meier method and log-rank test, as well as stratified multivariate models.
Postoperative complications and local toxicities
To address the third objective, the frequencies of soft tissue infection and noninfectious postoperative complications (shock, hemorrhage, hematoma, seroma, persistent postoperative fistula, or nonhealing surgical wound) within 1 year of diagnosis were compared by use of the c 2 test. Multivariate logistic regression was used to calculate adjusted odds of infectious and noninfectious complications. Risks of breast pain, fat necrosis, pneumonitis, and rib fracture were compared by use of the log-rank test. Analyses were 2 tailed (SAS software, version 9.2; SAS Institute, Cary, NC). The details are shown in Tables E1, E2 , and E3.
Results
Baseline characteristics
Among the 35,947 patients, the median follow-up was 3.5 years (interquartile range, 2.7-4.8 years). The median age was 75 years (interquartile range, 70-80 years), 5.8% of patients (nZ2089) were black, and 12.3% (nZ4419) had moderate to severe comorbidity. A total of 79.9% (nZ28,718) were diagnosed with invasive breast cancer and 20.1% (nZ7229) with pure DCIS. Of the patients, 23% (nZ8254) received lumpectomy alone, 3.6% (nZ1310) received brachytherapy, and 73.4% (nZ26,383) received EBRT.
Brachytherapy use increased from 0.8% of patients (45 of 5959) in 2002 to 6.9% of patients (403 of 5850) in 2007 (P<.001 for trend), whereas EBRT use decreased (P<.001 for trend) and use of lumpectomy alone remained stable (PZ.09 for trend) (Fig. 1 ). Patients treated with brachytherapy, in comparison with lumpectomy alone and EBRT, were more likely to have a tumor size of 2.0 cm or less, ER-positive receptor status, nonehighgrade histology, and negative axillary lymph nodes and were more likely to undergo axillary surgery but were less likely to have DCIS (P<.001 for all comparisons) and less likely than patients treated with EBRT to receive chemotherapy (P<.001) ( Table 1 ).
Subsequent mastectomy risk: invasive breast cancer
During follow-up, 1.8% of patients with invasive breast cancer (509 of 28,718) underwent subsequent mastectomy. The 5-year cumulative incidence of subsequent mastectomy was 4.7% (95% confidence interval [CI], 4.1%-5.4%) (number at risk, 5588) for those treated with lumpectomy alone, 2.8% (95% CI, 1.8%-4.3%) (number at risk, 1131) for brachytherapy, and 1.3% (95% CI, 1.1%-1.5%) (number at risk, 21,999) for EBRT ( Table 2 , Fig. 2A ).
On adjusted analysis, compared with lumpectomy alone as the referent (hazard ratio [HR], 1.00), both brachytherapy (HR, 0.61; 95% CI, 0.40-0.94; PZ.02) and EBRT (HR, 0.22; 95% CI, 0.18-0.28; P<.001) were associated with lower subsequent mastectomy risks. However, compared with brachytherapy as the referent, EBRT maintained the lowest subsequent mastectomy risk (HR, 0.37; 95% CI, 0.24-0.55; P<.001). Other predictors of subsequent mastectomy included ER-negative status, large tumor size, T4 stage, and high grade (Table 3) .
Propensity score analysis
Propensity score matching balanced covariates in treatment groups (Table E4) Comparing lumpectomy, breast brachytherapy, and external radiation 277 (Fig. 3A-C) . Similar magnitudes of relative risks (RRs) within each ASTRO group were confirmed by the nonsignificant interaction term between treatment group and ASTRO group (PZ.84 for interaction). Comparing brachytherapy with lumpectomy alone, we found similar risk reductions for suitable (adjusted HR, 0.60; 95% CI, 0.30-1.22; PZ.16), cautionary (adjusted HR, 0.55; 95% CI, 0.23-1.29; PZ.17), and unsuitable (adjusted HR, 0.57; 95% CI, 0.21-1.56; PZ.27) patients, although these comparisons were not statistically significant.
Although ASTRO groups failed to show a differential relative benefit from brachytherapy, the ASTRO suitable group did identify patients with the lowest baseline risk of subsequent mastectomy. Accordingly, within the suitable group, absolute risks after treatment with brachytherapy compared with EBRT were most similar. Specifically, the 5-year cumulative incidence of subsequent mastectomy was 1.6% (95% CI, 0.7%-3.5%) for brachytherapy versus 0.8% (95% CI, 0.6%-1.1%) for EBRT in suitable patients, as compared with 5.4% (95% CI, 2.5%-11.6%) versus 2.2% (95% CI, 1.7%-2.8%) in cautionary patients and with 3.6% (95% CI, 1.3%-9.4%) versus 1.6% (95% CI, 1.3%-2.0%) in unsuitable patients (Table 2) .
Brachytherapy outcomes were particularly favorable in older suitable patients (nZ7450) ( Table 2 , Fig. 3 D) , with a 5-year cumulative incidence of subsequent mastectomy of 3.5% (95% CI, 2.4%-5.0%) for lumpectomy alone, 1.0% (95% CI, 0.3%-3.4%) for brachytherapy, and 0.8% (95% CI, 0.6%-1.1%) for EBRT. The adjusted subsequent mastectomy reduction for brachytherapy versus lumpectomy alone was marginally significant (HR, 0.39; 95% CI, 0.15-1.02; PZ.05).
Subsequent mastectomy risk: DCIS
During follow-up, 2.2% of DCIS patients (156 of 7229) underwent subsequent mastectomy. The 5-year cumulative incidence Abbreviations: ASTRO Z American Society for Radiation Oncology; Brachy Z brachytherapy; EBRT Z external beam radiation therapy; SEER Z Surveillance, Epidemiology, and End Results. Cell sizes of less than 11 are reported with limited precision in accordance with the data-use agreement for this dataset. In some cases adjacent cells have also been reported with limited precision to prevent calculation of cell values of less than 11.
* P value from c 2 test comparing type of treatment (external beam radiation therapy, brachytherapy, or no radiation with covariate). y Applies to invasive cases only. z Overlapping lesion refers to the coded site of involvement in the breast and has been used by other groups as a surrogate for multicentricity (2) but is not specific for this clinical-pathologic feature.
x Fewer than 11 patients had missing values for these variables. Such patients were assumed to have a value for these variables equal to the median population value. k Per 100,000 persons. { Per 1,000,000 persons.
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Comparing lumpectomy, breast brachytherapy, and external radiation 279 Abbreviations: ASTRO Z American Society for Radiation Oncology; Brachy Z brachytherapy; DCIS Z ductal carcinoma in situ; Lump Z lumpectomy alone. of subsequent mastectomy was 3.2% (95% CI, 2.5%-4.1%) (number at risk, 2666) for those treated with lumpectomy alone, 4.6% (95% CI, 2.0%-10.5%) (number at risk, 179) for brachytherapy, and 1.6% (95% CI, 1.3%-2.2%) (number at risk, 4384) for EBRT ( Table 2 , Fig. 2 B) . Compared with lumpectomy alone, EBRT showed a lower risk of subsequent mastectomy (HR, 0.40; 95% CI, 0.28-0.55; PZ0.54) ( Table 3) .
Postoperative complications (all patients)
Within 1 year of diagnosis, the frequency of postoperative infections was 9.9% (95% CI, 9.2%-10.5%) for lumpectomy alone, 16.5% (95% CI, 14.5%-18.5%) for brachytherapy, and 11.4% (95% CI, 11.0%-11.8%) for EBRT (P<.001 for each pair-wise comparison) (Table 3) . On adjusted analysis, compared with lumpectomy alone as the referent, brachytherapy was associated with an increased postoperative infection risk (RR, 1.54; 95% CI, 1.33-1.77; P<.001), but EBRT showed no difference (RR, 1.03; 95% CI, 0.94-1.11; P<.001) ( Table E5 ).
The frequency of noninfectious postoperative complications was 6.0% (95% CI, 5.5%-6.5%) for lumpectomy alone, 18.7% (95% CI, 16.6%-20.8%) for brachytherapy, and 9.5% (95% CI, 9.1%-9.8%) for EBRT (P<.001 for each pair-wise comparison) ( Table 3) . After adjustment, compared with lumpectomy alone as the referent, brachytherapy was associated with an increased noninfectious complication risk (RR, 2.81; 95% CI, 2.43-3.24; P<.001), as was EBRT (RR, 1.37; 95% CI, 1.24-1.52; P<.001) (Table E5 ).
Local toxicities (all patients)
Brachytherapy was associated with a higher 5-year cumulative incidence of breast pain (22.9%; 95% CI, 20.2%-25.7%) compared with lumpectomy alone (11.2%; 95% CI, 10.5%-12.0%) or EBRT (16.7%; 95% CI, 16.2%-17.2%) (P<.001 for both comparisons). Brachytherapy was associated with a higher cumulative incidence of fat necrosis (15.3%; 95% CI, 13.0%-17.9%) compared with lumpectomy alone (5.3%; 95% CI, 4.8%-5.8%) or EBRT (7.7%; 95% CI, 7.3%-8.0%) (P<.001 for both comparisons). In contrast, brachytherapydcompared with lumpectomy alone and compared with EBRTdyielded no difference in the cumulative incidence of rib fracture (PZ.93 and PZ.07, respectively) or radiation pneumonitis (PZ.08 and PZ.07, respectively) ( Table 2) .
Discussion
In this cohort of older patients, for invasive breast cancer, brachytherapy was associated with an improved likelihood of breast preservation compared with lumpectomy alone but with a lesser magnitude of benefit compared with EBRT. Specifically, we found a 39% adjusted relative benefit for brachytherapy after lumpectomy versus a 78% adjusted relative benefit for EBRT. As practiced in this era, brachytherapy was associated with increased postoperative and local toxicity risks. This analysis adds to the literature a direct comparison of contemporary breast brachytherapy results against both a negative control group (lumpectomy alone) and a positive control group (EBRT) when applied in everyday US practice during the study era.
Previous randomized and population-based studies established a 70% local control benefit for adjuvant EBRT compared with lumpectomy alone for invasive breast cancer (7), consistent with the magnitude of subsequent mastectomy benefit for EBRT reported in our analysis. In contrast, the magnitude of relative improvement in local control for adjuvant brachytherapy compared with lumpectomy alone has, to date, been unclear. In the United States, the use of brachytherapy, a category 2a treatment option, has increased steadily whereas the use of lumpectomy alone, a category 1 treatment option, has remained static (8) . This apparent discordance between care patterns and the best evidence underscores the timeliness of our detailed evaluation of brachytherapy versus other treatment options.
Unlike the intermediate breast-preservation benefit associated with brachytherapy in our study, historical comparisons of brachytherapy versus EBRT showed equivalent tumor control outcomes. Patients in these studies were treated by use of interstitial brachytherapy techniques to radiate a 1.5-to 3.0-cm rim of tissue surrounding the lumpectomy cavity (9) (10) (11) . In contrast, in the vast majority of US patients treated in our study era, singleentry catheters were used, which radiate a smaller volume (1.0-cm rim of tissue) (3, 12) . This difference could contribute to our contrasting findings and underscores the need for continued evaluation of modern breast brachytherapy outcomes.
No prior study has shown brachytherapy suitability selection criteria to be valid for identifying patients with a differential treatment benefit after brachytherapy versus EBRT. After stratification by suitability criteria in our study, we found that suitable patients were least likely to undergo subsequent mastectomy and had the smallest absolute difference in mastectomy risk (<1% Fig. 2 . Adjusted subsequent mastectomy risk (cumulative incidence) in invasive breast cancer patients (A) and ductal carcinoma in situ (DCIS) patients (B). P ) indicates adjusted P value from proportional hazards regression with lumpectomy alone (Lump) as referent; P Abbreviations: CI Z confidence interval; DCIS Z ductal carcinoma in situ; EBRT Z external beam radiation therapy; HR Z hazard ratio; SEER Z Surveillance, Epidemiology, and End Results.
* Interaction of type of treatment with tumor behavior was significant at PZ.01.
y Per 100,000 persons in county of residence.
absolute difference at 5 years) when treated with brachytherapy versus EBRT. This observation suggests that ASTRO criteria are most informative for predicting patients' baseline risk of mastectomy without radiation and therefore for quantifying absolute gains in breast preservation attributable to radiation, consistent with another recent study evaluating ASTRO criteria (13) . However, our analysis showed that the proposed ASTRO groups did not show differential relative treatment benefits, with the adjusted relative benefits of brachytherapy within each ASTRO group nearly identical. Suitable patients aged 70 years or older derived adjuvant benefit from brachytherapy (HR, 0.39) that nearly approached the benefit derived from EBRT (HR, 0.22) (0.2% absolute difference at 5 years).
Limitations
Despite covariate adjustment as well as the validating propensity score model analysis to account for imbalances between treatment groups, residual confounding may still exist in this observational analysis, for example, with factors such as compliance with adjuvant hormonal therapy and margin status, which were unavailable in our data. The outcome of subsequent mastectomy, though clinically relevant (4, 14) , is only a proxy for local recurrence, although nevertheless, it is also known to be associated with recurrence risk factors (ER negativity, tumor stage/ grade, radiation delay, and incompletion). The low number of patients with DCIS treated with brachytherapy in this study precluded definitive comparison of the effectiveness of brachytherapy in this patient population. Furthermore, we focused our evaluation on ASTRO guidelines; other breast brachytherapy patient selection guidelines exist, and future studies may seek to validate other selection algorithms (15) (16) (17) . Absolute risk differences by treatment group were small, and therefore, when placed in a clinical context, counseling of patients about the relative tradeoffs between lumpectomy alone versus either brachytherapy or EBRT requires discussion of the clinical significance of both absolute and relative treatment effectsdparticularly in the older, most favorable low-risk patients. Future studies, with longer follow-up will be important, however, because recurrence and mastectomy risks increase with time. Importantly, the complication profile of brachytherapy may have continued improving since 2007, as provider experience has increased or newer catheters have provided greater dosimetric flexibility. The generalizability of our findings requires validation in patients treated more recently and in centers that favor intraoperative or interstitial brachytherapy, for whom outcomes could substantially vary because of differing treatment techniques (11, 13, 18, 19) . Improved technique could potentially impact breastpreservation rates, decreasing subsequent mastectomies because of treatment toxicity alone. Finally, it is important to acknowledge that whole-breast radiation is not without late toxicities, such as cardiac events and second malignancies, and although such outcomes are difficult to ascertain given the median follow-up of this study, they should not be neglected when one is evaluating the comparative effectiveness and toxicities of different radiation treatment options.
Conclusions
For older women with invasive breast cancer, brachytherapy generally offered a lesser breast-preservation benefit compared with standard EBRT, although absolute differences were minimal in suitable-risk patients. Future studies may seek to identify additional criteria to select optimal patient subgroups in which treatment benefits of brachytherapy are equivalent to EBRT. 
